Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to enfuvirtide, the first HIV fusion inhibitor.

The Journal of antimicrobial chemotherapy - 1 Aug 2004

Greenberg Michael L, Cammack Nick

Abstract excerpt

Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Enfuvirtide
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to HIV Infections

Share to Mutation

Share to Peptide Fragments

Source

Identifiers

PMID: 15231762
DOI: 10.1093/jac/dkh330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to enfuvirtide, the first HIV fusion inhibitor.PMID 15231762Read ↗

Enfuvirtide: the first HIV fusion inhibitorSemantic proximity Read ↗

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Semantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

HIV fusion and its inhibition in antiretroviral therapySemantic proximity Read ↗

Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtideSemantic proximity Read ↗

Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion ProteinsSemantic proximity Read ↗

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.Semantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion.Semantic proximity Read ↗

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.Semantic proximity Read ↗

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.